Galecto Inc Ordinary Shares GLTO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GLTO is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.67
- Day Range
- $0.65–0.70
- 52-Week Range
- $0.50–3.70
- Bid/Ask
- $0.68 / $0.68
- Market Cap
- $18.14 Mil
- Volume/Avg
- 26,332 / 221,048
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.galecto.com
Comparables
Valuation
|
Metric
|
GLTO
|
CBAY
|
RYTM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.56 | 12.65 | 13.90 |
Price/Sales | — | 111.01 | 29.58 |
Price/Cash Flow | — | — | — |
Price/Earnings
GLTO
CBAY
RYTM
Financial Strength
|
Metric
|
GLTO
|
CBAY
|
RYTM
|
|---|---|---|---|
Quick Ratio | 5.98 | 10.70 | 5.27 |
Current Ratio | 6.31 | 10.96 | 5.58 |
Interest Coverage | — | −5.27 | −13.26 |
Quick Ratio
GLTO
CBAY
RYTM
Profitability
|
Metric
|
GLTO
|
CBAY
|
RYTM
|
|---|---|---|---|
Return on Assets (Normalized) | −51.84% | −30.06% | −46.12% |
Return on Equity (Normalized) | −65.49% | −51.97% | −76.97% |
Return on Invested Capital (Normalized) | −68.38% | −30.87% | −76.40% |
Return on Assets
GLTO
CBAY
RYTM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rsdhzttd | Xjzc | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Grwzkgl | Xgwhqn | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mpmcnzb | Kwqsvm | $99.5 Bil | |
MRNA
| Moderna Inc | Ndbcbwbj | Wzzp | $38.8 Bil | |
ARGX
| argenx SE ADR | Jnqrtpm | Xbgc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nkhhwddt | Jkyl | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fwbfxqtl | Vkhntft | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vrljsnkyl | Dxxxg | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gxgglbljs | Ksmfqk | $12.5 Bil | |
INCY
| Incyte Corp | Ygjyrvvmw | Xtqrbf | $11.6 Bil |